AACR 2023 Archives - MediaMedic

New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC

By Mourabit Halima 2024.01.18

According to results from the phase 1a/1b LOXO-RAS-20001 study (NCT04956640) showcased at the 2023 American Association for Cancer Research (AACR) annual meeting, the KRAS G12C inhibitor LY3537982 exhibited clinical efficacy in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors. This is a phase I study of LY3537982 treating locally advanced/metastatic solid tumor patients with KRAS G12C mutation. It involves patients with an ECOG PS of 0-1, measurable disease according to RECIST v1.1 standards. The main objectives are to determine the recommended phase II dose (RP2D) of LY3537982, its safety, pharmacokinetics (PK), and antitumor activity. Patients were divided into four dosage groups: 50 mg, 100 mg, 150 mg, and 200 mg taken twice daily. Dose expansion cohorts included combination treatments of LY3537982 with pembrolizumab (for NSCLC) and cetuximab (for CRC).

Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies

By Mourabit Halima 2024.01.18

The 2023 American Association for Cancer Research (AACR) Annual Meeting was held in Orlando, USA, from April 14 to 19, 2023. Every year, the AACR Congress reports numerous clinical, basic, and translational studies on cancer, especially innovative therapies in the preliminary phase I/II research stages. At this year's AACR conference, three clinical trials were reported in the lymphoma field, including anti-CD19 immunotherapy Tafasitamab, CD19/CD20 CAR naive/memory T cells, and bispecific quadrivalent antibody (innate cell engager) AFM13.

IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

By Mourabit Halima 2024.01.18

Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high risk of recurrence following curative resection or ablation. The study's principal investigator, Professor Pierce Chow of the National Cancer Centre Singapore, revealed the trial's results, suggesting a potential paradigm shift in the management of high-risk HCC patients.

KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract

By Mourabit Halima 2024.01.18

According to the KEYNOTE-966 study results announced at the 2023 American Association for Cancer Research (AACR) annual meeting, adding pembrolizumab on the basis of gemcitabine and cisplatin brings statistically and clinically significant survival benefits to patients with advanced biliary tract cancer. These results validate the outcomes of the randomized phase III TOPAZ-1 study. Encouragingly, this approach demonstrated consistent survival benefits across geographical regions and PD-L1 expression subgroups. The KEYNOTE-966 study results were concurrently published in "The Lancet."

AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

By Mourabit Halima 2024.01.18

According to the preliminary results of the phase III AEGEAN trial (NCT03800134) interim analysis presented at the AACR Annual Meeting in 2023, in patients with resectable non-small cell lung cancer (NSCLC), the perioperative durvalumab combined with platinum-based neoadjuvant chemotherapy showed statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS) compared to placebo combined with chemotherapy.

Progress of ctDNA in predicting prognosis of patients with urological tumors

By Mourabit Halima 2024.01.18

Circulating tumor DNA (ctDNA) for predicting tumor prognosis and guiding individualized treatment is a hot topic in malignant tumor research. ctDNA exists in the peripheral blood of tumor patients in a cell-free state and can dynamically evaluate the tumor condition, overcoming tumor heterogeneity biases. The 2023 American Association for Cancer Research (AACR) Annual Meeting was held from April 14 to 19, 2023, in Orlando, USA. In this AACR conference, three ctDNA-related studies evaluated its application value in urological tumors.

New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC

By Lisa Cui 2024.01.18

Exploring New Breast Cancer Risk Genes, Biomarkers, and Prognostic Models at AACR 2023

By Mourabit Halima 2024.01.18

The American Association for Cancer Research (AACR) held its annual conference from April 14th to 19th, 2023 in Orlando, USA. With numerous reports on clinical, fundamental, and translational cancer research presented each year, this year's AACR conference delved deep into the realm of breast cancer. Research focused on the analysis of various susceptibility genes and risk-related biomarkers, aiming to discover new therapeutic targets and develop prognostic models, with the hope of providing improved services for patients.

Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies

By Mourabit Halima 2024.01.18

Dr. Lu Si: mRNA Vaccines and TIGIT Monoclonal Antibodies — New Stars of 2023 AACR

By Lisa Cui 2024.01.18

PD-1 inhibitors have become the international standard for adjuvant treatment of stage IIB-IV melanoma after surgery. Research on the neoadjuvant use of PD-1 monotherapy (pembrolizumab) for resectable melanoma was just published in the New England Journal of Medicine in March of this year. With this, PD-1 inhibitors cover the two major treatment areas of neoadjuvant and adjuvant treatment of melanoma. Two studies presented at this year's AACR conference have brought new breakthroughs to this field.